经直肠次谐波超声成像用于前列腺癌检测
这项IRB批准的首例人体研究纳入55名受试者,其中50名接受对比增强次谐波超声成像(SHI)及靶向穿刺活检。
要点
- 定量次谐波灌注参数诊断准确率最高达0.80。
核心结论
- 首例人体研究初步估计SHI检测临床显著前列腺癌的诊断准确率最高可达80%。
研究设计与样本
- IRB批准的前瞻性研究纳入55名受试者,前5名用于SHI优化,其余50名接受对比增强经直肠超声成像及靶向穿刺活检。
主要发现
- 50名受试者中检出22例前列腺癌,其中临床显著癌11例。
- 所有成像模态诊断准确率0.59至0.80,定量次谐波灌注估计最高。
临床怎么用
- SHI靶向活检可提高临床显著前列腺癌的检出,定量灌注参数有助风险分层。
局限性
- 为首例人体初步研究,样本量有限(50例分析),需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the prostate cancer (CaP) detection rates of contrast-enhanced, transrectal subharmonic ultrasound imaging (SHI). MATERIALS AND METHODS: This IRB-approved study enrolled 55 subjects. The initial 5 subjects were studied for SHI optimization, while the remaining 50 were evaluated with contrast-enhanced sonography using continuous SHI, color, and power Doppler as well as conventional grayscale, continuous color, and power Doppler and SHI combined with maximum flash replenishment. A maximum of 6 directed biopsy cores were obtained from sites of greatest asymmetrical enhancement, followed by spatially distributed cores in a double sextant distribution. Subharmonic time-intensity parameters, including time to peak intensity, peak intensity, and estimated perfusion were also evaluated for each directed biopsy core. Receiver operating characteristic curve analysis and conditional logistic regression were employed to assess the benefit of each modality and the quantitative SHI parameters. RESULTS: Cancer was detected in 22 of 50 subjects. Among subjects with clinically significant CaP (n = 11), targeted cores were more likely to be positive (odds ratio 1.39, P = .02). The majority of patients detected by SHI demonstrated significant CaP (5/8); SHI remained an independent marker of malignancy in a multivariate logistic regression model (P = .027). Receiver operating characteristic curve analysis of imaging findings compared to biopsy results yielded diagnostic accuracies ranging from 0.59 to 0.80 for all imaging modalities with the highest being for quantitative subharmonic perfusion estimates. CONCLUSION: This first-in-humans study provides a preliminary estimate of the diagnostic accuracy of SHI for detection of clinically significant CaP (up to 80%).
引用
- Gupta I, Freid B, Masarapu V, et al. Transrectal Subharmonic Ultrasound Imaging for Prostate Cancer Detection. Urology. 2019. PMID: 31899231. doi:10.1016/j.urology.2019.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。